Based on the results of CMap database inquiry, 15 types of small molecules drugs including ALK/ BCR-ABL/ BTK/ CDK /Met inhibitor, etc. were identified (Supplementary Table 16), eight small molecular drugs targeting TPM4 obtained (Supplementary Table 16), meaning that they have the potential to treat PRAD. Here, TPM4 is linked to prostate adenocarcinoma.